David Wojciechowski1, Flavio Vincenti. 1. University of California, San Francisco, Kidney Transplant Service, San Francisco, California 94143-0780, USA.
Abstract
PURPOSE OF REVIEW: This review will discuss the mechanism of action and important clinical trial data in renal transplantation for the small molecule Janus kinase (JAK) 3 inhibitor tofacitinib, formerly known as CP-690,550 and tasocitinib. RECENT FINDINGS: JAKs are cytoplasmic tyrosine kinases that participate in the signaling of a broad range of cell surface receptors, particularly members of the cytokine receptor common gamma (cγ) chain family. JAK3 inhibition has immunosuppressive effects and treatment with tofacitinib in clinical trials has demonstrated efficacy in autoimmune disorders such as psoriasis and rheumatoid arthritis. Nonhuman primate models of renal transplantation demonstrated prolonged graft survival with tofacitinib compared with vehicle control. Renal transplant clinical trials in humans have demonstrated tofacitinib to be noninferior to cyclosporine in terms of rejection rates and graft survival. There was also a lower rate of new-onset diabetes after transplant. However, there was a trend toward more infections, including cytomegalovirus and BK virus nephritis. SUMMARY: Tofacitinib may be a promising alternative to calcineurin inhibitors. The optimal therapeutic window is still being determined.
PURPOSE OF REVIEW: This review will discuss the mechanism of action and important clinical trial data in renal transplantation for the small molecule Janus kinase (JAK) 3 inhibitor tofacitinib, formerly known as CP-690,550 and tasocitinib. RECENT FINDINGS:JAKs are cytoplasmic tyrosine kinases that participate in the signaling of a broad range of cell surface receptors, particularly members of the cytokine receptor common gamma (cγ) chain family. JAK3 inhibition has immunosuppressive effects and treatment with tofacitinib in clinical trials has demonstrated efficacy in autoimmune disorders such as psoriasis and rheumatoid arthritis. Nonhuman primate models of renal transplantation demonstrated prolonged graft survival with tofacitinib compared with vehicle control. Renal transplant clinical trials in humans have demonstrated tofacitinib to be noninferior to cyclosporine in terms of rejection rates and graft survival. There was also a lower rate of new-onset diabetes after transplant. However, there was a trend toward more infections, including cytomegalovirus and BK virus nephritis. SUMMARY:Tofacitinib may be a promising alternative to calcineurin inhibitors. The optimal therapeutic window is still being determined.
Authors: Seemal R Desai; Ilona J Frieden; Joel M Gelfand; Whitney High; Arthur Kavanaugh; Ashfaq A Marghoob; David M Ozog; Ted Rosen; Linda Stein Gold; Bruce Strober; Neil Swanson; George Martin Journal: J Clin Aesthet Dermatol Date: 2015-09
Authors: Matthias A Fante; Ernst Holler; Barbara Schmidt; Daniel Wolff; Yvonne Ehrl; Annelie Plentz Journal: Bone Marrow Transplant Date: 2018-10-22 Impact factor: 5.483
Authors: Brendan Nichols; Prachi Jog; Jessica H Lee; Daniel Blackler; Michael Wilmot; Vivette D'Agati; Glen Markowitz; Jeffrey B Kopp; Seth L Alper; Martin R Pollak; David J Friedman Journal: Kidney Int Date: 2014-08-06 Impact factor: 10.612